purpose assess local control survival complications patients cervical carcinoma stage iib treated radically transperineal lowdose rate interstitial brachytherapy following external beam radiotherapy patients methods NUMBER women age years mean NUMBER years cervical carcinoma stage iib initially treated external beam radiotherapy telecobalt NUMBER mv linear accelerator dose NUMBER gy delivered weeks weeks completing external radiation patients received interstitial brachytherapy activity using perineal template median dose delivered implant volume NUMBER gy range gy delivered average dose rate NUMBER range point defined NUMBER cm lateral central uterine tandem level os taken representative assessing dose cervix mean doses delivered interstitial brachytherapy point cervix point b rectum NUMBER gy NUMBER gy NUMBER gy NUMBER gy respectively results median NUMBER months actuarial disease free survival overall survival NUMBER patients NUMBER NUMBER years NUMBER NUMBER respectively response radiotherapy strong predictor local control NUMBER patients continuing pelvic control initial complete response overall NUMBER patients persistent disease NUMBER developed central recurrence initial control patients developed distant metastasis patient immediate complication late toxicity included grade rectal reactions patients grade iv bladder complication fistula patients NUMBER years treatment patient developed intestinal obstruction relieved conservative management patients developed vaginal stenosis disease free survival NUMBER patients aged NUMBER years compared NUMBER patients NUMBER years p NUMBER dose cervical point prognostic indicator disease free survival NUMBER patients received NUMBER gy comparison NUMBER patients NUMBER gy p NUMBER difference local control survival patients minimal moderate parametrial involvement bulky disease NUMBER cm presentation longer gap external radiation brachytherapy showed trend inferior local control conclusions interstitial brachytherapy external beam irradiation patients cervical carcinoma stage iib results acceptable local control survival complication rates increased dose cervical disease results improved local control survival considered optimizing brachytherapy treatment plans comparison results standard intracavitary therapy remains proven randomized trial iridium NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER iridium NUMBER NUMBER NUMBER syed neblett NUMBER NUMBER NUMBER NUMBER follow follow treatment related ii vesico vaginal NUMBER NUMBER year NUMBER NUMBER year mci cm gy h gy h